Table 1.

Association of IFIT2 Expression Levels with Clinicopathologic Features in 53 Patients with OSCC

VariableNo. CasesIFIT2 <50%,*n (%)IFIT2 ≥50%,*n (%)P
Tumor stage
    T1-3135 (38.5)8 (61.5)0.292
    T4409 (22.5)31 (77.5)
Lymph node stage
    N0253 (12.0)22 (88.0)0.032
    N1-32811 (39.2)17 (60.8)
Clinical stage
    I-III93 (33.3)6 (66.7)0.684
    IV4411 (25.0)33 (80.0)
Tumor differentiation status
    Moderate + poor2911 (37.9)18 (62.1)0.023
    Good222 (9.1)20 (90.0)
  • * The patients were divided into two groups based on IFIT2 immunostaining: a high-IFIT2 expression group, having positive IFIT2 immunostaining in ≥50% of the cells analyzed, and a low-IFIT2 expression group, having positive IFIT2 immunostaining in <50% of the cells analyzed.

  • Fisher's exact test (two sided).